Janssen Submits Supplemental New Drug Application To U.S. FDA Seeking Expanded Pediatric Indication For HIV-1 Therapy Edurant
Portfolio Pulse from Benzinga Newsdesk
Janssen, a pharmaceutical company of Johnson & Johnson (JNJ), has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for an expanded pediatric indication for its HIV-1 therapy, Edurant.
July 28, 2023 | 7:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The submission of a sNDA by Janssen, a subsidiary of Johnson & Johnson, for expanded pediatric use of its HIV-1 therapy, Edurant, could potentially boost JNJ's market share in the HIV treatment market if approved.
The news of Janssen's sNDA submission to the FDA for expanded pediatric use of Edurant is directly related to Johnson & Johnson, as Janssen is a subsidiary of JNJ. If the FDA approves the sNDA, it could potentially increase JNJ's market share in the HIV treatment market, which would likely have a positive impact on JNJ's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100